<DOC>
	<DOCNO>NCT02250612</DOCNO>
	<brief_summary>The purpose double-masked , randomize , control study ass safety ocular hypotensive efficacy four different dos SYL040012 ( bamosiran ) eye drop compare Timolol maleate 0.5 % 28 treatment day patient elevate intraocular pressure .</brief_summary>
	<brief_title>SYL040012 , Treatment Open Angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Patients older 18 year either sex Good fair general health assess investigator . Signed informed consent prior clinical trialrelated procedure Diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OHT ) Postwashout mean IOP target range BCVA 1.0 logMAR well ETDRS eye ( equivalent 20/200 ) Stable visual field Central corneal thickness 480620 μm Shaffer gonioscopic grade ≥ 3 ( least 3 quadrant ) eye Pregnant breastfeeding female Females childbearing potential willing use medically acceptable contraceptive method Clinically significant systemic disease Changes systemic medication could substantial effect IOP Known hypersensitivity component formulation Unable comply clinical trial requirement Clinically significant abnormality laboratory test Severe visual field defect Any secondary glaucoma Pseudoexfoliation pigment dispersion component , history angle closure narrow angle . IOP ≥ 35 mm Hg eye Previous nonlaser glaucoma surgery glaucoma laser procedure ( e.g. , laser trabeculoplasty ) refractive surgery Any ocular surgery laser treatment , cataract extraction ocular trauma within 6 month prior Baseline Evidence ocular infection , inflammation , clinically significant blepharitis conjunctivitis baseline ( Visit 0 ) , history herpes simplex keratitis Clinically significant ocular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>SYL040012</keyword>
	<keyword>bamosiran</keyword>
	<keyword>siRNA</keyword>
	<keyword>RNAi</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
</DOC>